FDA Approves First mRNA-based Flu Shot for Seniors

The Food and Drug Administration (FDA) has approved the first mRNA-based flu vaccine, paving the way for a new type of shot that will be available for adults 50 and over looking to get immunized against the respiratory illness, Moderna announced Wednesday evening.

The agency granted approval to Moderna’s vaccine for adults ages 50 to 64 and accelerated approval for those 65 and older with a commitment to further study the shot in older adults in a post-marketing study, according to Moderna. The company said the new shot will probably be available in select retailers in the coming weeks. A price was not immediately available.

Medical experts have expressed hope that mRNA vaccines could make it easier for manufacturers to respond quicker to changes in the flu strain because they are faster to develop than traditional shots.

Please select this link to read the complete article from The Washington Post.